Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs BRICANYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute asthma exacerbation,Off-label: Management of acute hyperkalemia,Off-label: Prevention of preterm labor (terbutaline)
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Metabolized in the liver via sulfonation (sulfotransferase enzymes) and to a minor extent by catechol-O-methyltransferase (COMT).
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Approximately 25% bound to albumin.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
~0.6 L/kg; indicates distribution into total body water.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Inhalation: ~10-20% (dependent on device and technique); Oral: ~15-20% (due to extensive first-pass metabolism).
No dose adjustment required. Topical use with minimal systemic absorption.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential for increased systemic exposure.
No dose adjustment required. Topical use with minimal systemic absorption.
No specific dose adjustment recommended; caution in severe hepatic impairment (Child-Pugh Class C) due to reduced clearance.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Subcutaneous: 5-10 mcg/kg every 1-2 hours as needed (max 0.5 mg); Intravenous: 5-10 mcg/kg over 1 minute (max 0.5 mg); Inhalation (MDI): 1-2 inhalations (0.2-0.4 mg) every 4-6 hours; Nebulized: 0.01-0.03 mg/kg (max 1 mg) every 6-8 hours.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
Initiate at lower end of dosing range (e.g., subcutaneous 0.125 mg); monitor for tachycardia, hypertension, and tremor; consider age-related decline in renal and hepatic function.
No FDA black box warning.
Not available
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Paradoxical bronchospasm may occur,Cardiovascular effects (e.g., tachycardia, arrhythmias, increased blood pressure) use caution with cardiovascular disorders,Hypokalemia may occur,Hyperglycemia reported,Immediate hypersensitivity reactions
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to any component,Tachydysrhythmias,Cardiac glycoside toxicity with arrhythmias
No known food interactions with topical Aclovate.
No significant food interactions. However, avoid excessive caffeine intake (coffee, tea, cola) as it may exacerbate beta-agonist side effects like palpitations and tremor.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limited data suggest no major malformations. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and transient hypocalcemia. Avoid in preterm labor due to maternal and fetal adverse effects.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Excreted into breast milk in small amounts; M/P ratio approximately 2.5. No adverse effects reported in infants at therapeutic maternal doses. However, monitor infant for signs of beta-2 adrenergic stimulation (e.g., tachycardia, irritability). Consider risk-benefit.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No specific dose adjustments recommended for asthma or COPD. However, in preterm labor (off-label), use lowest effective dose and shortest duration due to increased risk of maternal pulmonary edema, cardiac ischemia, and fetal effects. Monitor closely.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
BRICANYL (terbutaline sulfate) is a beta-2 adrenergic agonist used for bronchodilation in asthma and COPD. It can cause transient hypokalemia, hyperglycemia, and tremor. Use with caution in patients with diabetes, hypertension, or hyperthyroidism. Monitor serum potassium in patients on diuretics or with hypoxia. Not recommended for acute severe asthma as monotherapy; prefer short-acting beta-agonists like albuterol.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use.,Rinse mouth with water after inhalation to prevent oral thrush.,Seek emergency medical help if breathing problems worsen or if you have chest pain or irregular heartbeat.,Monitor blood sugar if diabetic as this medication may raise blood glucose levels.,Avoid caffeine as it may increase side effects like nervousness and rapid heart rate.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs BRICANYL, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. BRICANYL is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and BRICANYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of BRICANYL is: Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and BRICANYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . BRICANYL is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.